Germany· DE-A57-fd778951689187e8
Profact Depot
A buserelin product containing buserelin acetate, registered in Germany by Cheplapharm Arzneimittel Gmbh. The same ATC class is registered in 8 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Buserelin is registered in 8 of 19 countries.
Countries holding a registration under ATC L02AE01 (buserelin), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 4 of them publish a price we can compare per daily dose
Buserelin · ATC L02AE01
8 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Germany
- Icelandprice
- Italyprice
- Netherlands
- United Kingdom
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Buserelin Acetate
- Manufacturer
- Cheplapharm Arzneimittel Gmbh
- Country
- Germany (DE)
- ATC code
- L02AE01
- ATC class
- Buserelin
- Defined daily dose
- 0.11 mg, Implantat
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Buserelin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBusol vetaniMedica GmbH
- United KingdomBuserelin 5.5mg/5.5ml solution for injection vialsNeon Healthcare Ltd
- SwedenSuprecur 0,15 mg/dos Nässpray, lösningCheplapharm Arzneimittel GmbH
- ItalySUPREFACT*1 fiala SC 5,5 ml 1 mg/mlCHEPLAPHARM ARZNEIMITTEL GMBH
- SpainSUPREFACT 1 mg/ml SOLUCION INYECTABLECheplapharm Arzneimittel Gmbh
- NetherlandsSuprefact Depot 3 maanden, implantatiestift 9,45 mgMedcor Pharmaceuticals B.V.
- CanadaSUPREFACTCHEPLAPHARM ARZNEIMITTEL GMBH
- BelgiumSuprefact Nasal 0.1 mgSanofi Belgium
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Austria · Suprecur, Suprefact
- Bulgaria · Супрефакт Депо 3 Месеца
- Spain · Suprefact, Suprefact Depot
- United Kingdom (Northern Ireland) · Buserelin, Suprecur Injection
- Greece · Suprefact Depot 3 Μήνεσ
- Hungary · Suprefact
- Italy · Suprefact, Suprefact Depot
- Netherlands · Suprefact Depot
- Sweden · Suprecur, Suprefact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/554c208b-6812-4d9d-9ebe-2d5ebd34610f GET /v1/drugs/554c208b-6812-4d9d-9ebe-2d5ebd34610f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Subcutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Buserelin Acetate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about buserelin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.